Announced Thu, 20 Aug, 2026 · 16:29 IST
IOL CP Q1 FY27: Revenue up 37%, PAT up 90%, guides 15-20% growth
Mgmt Guided Margin ImprovementMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.0%1-day move
₹164.14
prior close
₹164.49
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3-0.1-1.1-0.8+3.0+5.7+13.6+17.3+18.2+16.4+18.8+23.2——
Up moveDown movePending
AI summary
IOL Chemicals Q1 FY27 revenue grew 37% YoY to INR756 cr, EBITDA up 61% to INR111 cr (margin 14.6% vs 12.4%), PAT up 90% to INR64.5 cr. Exports at 28.5% of revenue. Non-ibuprofen APIs now 43% of pharma revenue, up from 36%. FY27 guidance: 15-20% revenue growth, EBITDA margin 14-15%. FY28 guidance: 15-20% revenue, 15-17% EBITDA margin. New Triacetin product has about INR120 cr annual revenue potential.
Likely market impact
Strong Q1 beat with margin expansion; confident FY27-28 guidance signals sustained growth; non-ibuprofen diversification is delivering.